JPH03148208A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPH03148208A JPH03148208A JP28480689A JP28480689A JPH03148208A JP H03148208 A JPH03148208 A JP H03148208A JP 28480689 A JP28480689 A JP 28480689A JP 28480689 A JP28480689 A JP 28480689A JP H03148208 A JPH03148208 A JP H03148208A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- antibacterial agent
- synthetic bentonite
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 32
- 239000000440 bentonite Substances 0.000 claims abstract description 31
- 229910000278 bentonite Inorganic materials 0.000 claims abstract description 31
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims abstract description 31
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920002545 silicone oil Polymers 0.000 claims abstract description 13
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims abstract description 8
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims abstract description 8
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims abstract description 7
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims abstract description 7
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 claims abstract description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 6
- 239000000194 fatty acid Substances 0.000 claims abstract description 6
- 229930195729 fatty acid Natural products 0.000 claims abstract description 6
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 4
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930007845 β-thujaplicin Natural products 0.000 claims abstract description 4
- -1 photosensor No. 201 Chemical compound 0.000 claims description 10
- 239000002994 raw material Substances 0.000 abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 abstract description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 abstract description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract description 7
- 229960001755 resorcinol Drugs 0.000 abstract description 4
- 239000003504 photosensitizing agent Substances 0.000 abstract description 2
- IPGANOYOHAODGA-UHFFFAOYSA-N dilithium;dimagnesium;dioxido(oxo)silane Chemical compound [Li+].[Li+].[Mg+2].[Mg+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O IPGANOYOHAODGA-UHFFFAOYSA-N 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 35
- 239000004094 surface-active agent Substances 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 13
- 231100000321 erythema Toxicity 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000006071 cream Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 9
- 238000004945 emulsification Methods 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052901 montmorillonite Inorganic materials 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は抗菌力を有する皮膚外用剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a skin external preparation having antibacterial activity.
更に詳しくは少量の抗菌剤の配合で、抗菌力を発揮し、
皮膚に対する安全性、安定性、官能面においても優れた
皮膚外用剤に関する。In more detail, it is formulated with a small amount of antibacterial agent to demonstrate antibacterial power,
This invention relates to an external skin preparation that is excellent in terms of safety, stability, and sensory aspects for the skin.
化粧品、医薬品には抗菌剤を含んだ各種の製剤がある。 Cosmetics and pharmaceuticals include various preparations containing antibacterial agents.
そして、その剤形はさまざまである。その剤形の中でク
リーム状、乳l&状のものは、最も官能や使用感が良好
である。And its dosage forms vary. Among these dosage forms, cream-like and milky-like forms have the best organoleptic sensation and feeling of use.
しかしながら、このようなエマルジョンタイプのものと
するために界面活性剤を配合すると、多くの抗菌剤は界
面活性剤の入ったクリーム等ではその効果が減少し、抗
菌剤の量を多くせざるを118す、安全性や有効性の面
で問題があった。However, when a surfactant is added to create such an emulsion type product, the effectiveness of many antibacterial agents decreases in creams containing surfactants, and the amount of antibacterial agent must be increased. However, there were problems in terms of safety and efficacy.
界面活性剤は、皮膚に対する安全性についても十分とは
いえない。Surfactants are also not sufficiently safe for the skin.
そこで界面活性剤を用いない乳化方法について種々研究
されている。その1つに合成ベントナイトを用いる乳化
方法か知られている。ベントナイトは天然に存在する特
殊コロイド性粘土であり、モンモリロン石を主とした粘
土である。天然物では不純物が多く強固なゲルを形成し
ないが、金属の種類を替え、純度をあげ白色化したケイ
酸マグネシウム、リチウムすなわち合成ベントナイトを
用いると、そのゲルはチクソトロピー性が高く、化粧料
に配合して用いることができる。Therefore, various studies are being conducted on emulsification methods that do not use surfactants. One known method is an emulsification method using synthetic bentonite. Bentonite is a special colloidal clay that occurs naturally, and is mainly composed of montmorillonite. Natural products have many impurities and do not form strong gels, but when the type of metal is changed to improve the purity and use whitened magnesium silicate, lithium, or synthetic bentonite, the gel has high thixotropy and can be incorporated into cosmetics. It can be used as
特開昭60−178.803号公報には、リチウム・モ
ンモリロナイト水膨潤ゲル体を基礎化粧品クリーム類の
水ベースとして使用した基礎化粧品が記載されているが
、ベントナイトを基礎化粧品に使用することは従来より
公知であるので、この公報はリチウム・モンモリロナイ
ト水膨潤ゲル体と植物蛋白質を用いて節分を水中へ分散
させるものと考えられる。JP-A No. 60-178.803 describes basic cosmetics using lithium-montmorillonite water-swollen gel as the water base for basic cosmetic creams, but the use of bentonite in basic cosmetics has never been done before. Since this publication is well known, it is believed that this publication uses a lithium-montmorillonite water-swellable gel body and a plant protein to disperse setsubun into water.
このように合成ベントナイトはゲル化剤として化粧料に
広く用いられているが、界面活性剤を配合せず合成ベン
トナイトのみでエマルジョンを形成させる場合、エマル
ジョンの粒子が粗く、経時的に固化する傾向があり、ま
た官能面でもきしみ感があり、製品として用いることが
できなかった。As described above, synthetic bentonite is widely used in cosmetics as a gelling agent, but when an emulsion is formed using only synthetic bentonite without adding a surfactant, the particles of the emulsion are coarse and tend to solidify over time. However, it also had a squeaky feel in terms of organoleptic aspects, and could not be used as a product.
一方、シリコン油も化粧料として広く利用されているが
、シリコン油は乳化しにくい物質とされ、消泡剤として
用いられている。On the other hand, silicone oil is also widely used as a cosmetic, but silicone oil is considered to be a substance that is difficult to emulsify and is used as an antifoaming agent.
シリコン油を合成ベントナイトと組み合わせて使用され
た例はなく、また通常2%未満で用いるのが通例であっ
た。There have been no examples of silicone oil being used in combination with synthetic bentonite, and it was customary to use it at less than 2%.
このように界面活性剤を配合しない化粧品はさまざまな
試みがなされてきたが、実際製品として用いることがで
きる製品はなかった。Although various attempts have been made to create cosmetics that do not contain surfactants, none of them have been able to be used as actual products.
このように界面活性剤を用いない化粧料の乳化方法は、
従来の技術として、作成すること自体は不可能ではなか
ったが、従来の界面活性剤を用いない乳化化粧料は製品
として用いるためには、キメの細かさ、安定性、きしみ
感などの官能性、クリームのような物性等が不十分であ
り、満足な結果が得られていない。This method of emulsifying cosmetics without using surfactants is
Although it is not impossible to create conventional emulsified cosmetics without using surfactants, in order to use them as products, they must have fine texture, stability, and sensuality such as squeaky feel. , cream-like physical properties, etc. are insufficient, and satisfactory results have not been obtained.
本発明のl]的は、抗菌剤を配合した皮膚外用剤におい
て抗菌剤の効果を減少させることなく、従って少量の抗
菌剤の配合で抗菌力を保持しながら乳化した皮膚外用剤
を提供することであり、界面活性剤を使用することなく
、乳化物が安定であり、キメが細かく、きしみ感など使
用に当っての不快感がなく、クリーム等としての物性に
おいて優れ、かつ皮膚に対し安全性が保証された抗菌剤
配合皮膚外用剤を提供することである。The object of the present invention is to provide an emulsified skin preparation containing an antibacterial agent without reducing the effect of the antibacterial agent, and thus retaining antibacterial activity with a small amount of antibacterial agent. The emulsion is stable without the use of surfactants, has a fine texture, does not cause discomfort when used such as a squeak, has excellent physical properties as a cream, etc., and is safe for the skin. The purpose of the present invention is to provide an antibacterial agent-containing external skin preparation that is guaranteed to be safe.
更に抗菌剤配合皮膚外用剤としてニキビ治療用皮膚外用
剤があるが、この場合、油剤の配合は極力少ない方がよ
く、また官能面でもさっばりした感触が好まれることか
ら、官能面において、浦感の少ない抗菌剤配合皮膚外用
剤を提供する。Furthermore, there are topical skin preparations for treating acne that contain antibacterial agents, but in this case, it is better to contain as little oil as possible, and a light feel is preferred from a sensory standpoint. To provide an external preparation for skin containing an antibacterial agent that is less sensitive.
本発明者らは前記課題を解決するため鋭意研究を行った
。The present inventors conducted extensive research to solve the above problems.
抗菌剤の抗菌力を保持させるために、最も有効な手段は
界面活性剤を使用しないことである。従っで界面活性剤
を使用しない乳化方法について、皮膚外用剤として利用
できる数多くの物質について、検討を行ったが、角ll
決するに到らながった。The most effective means for preserving the antibacterial activity of antibacterial agents is not to use surfactants. Therefore, we have investigated many substances that can be used as external preparations for the skin regarding emulsification methods that do not use surfactants.
I couldn't reach a decision.
そこで皮膚外用剤に通常用いられる量を無視し、量的変
化も考慮して実験しなおしたところ、合成ベントナイト
と共にシリコン油を多量に使用することによって前記課
題を一挙に解決しうろことを見いだし本発明を完成した
。Therefore, we ignored the amounts normally used in external skin preparations and re-experimented by taking into account quantitative changes, and discovered that we could solve the above problems at once by using a large amount of silicone oil together with synthetic bentonite. Completed the invention.
すなわち本発明は、少なくとも合成ベントナイトとシリ
コン油と抗菌剤とを配合してなる皮膚外用剤である。That is, the present invention is an external preparation for skin that contains at least synthetic bentonite, silicone oil, and an antibacterial agent.
合成ベントナイトを0.1〜5.0重量%、シリコン油
を2〜30重量%含有することが好ましい。It is preferable to contain 0.1 to 5.0% by weight of synthetic bentonite and 2 to 30% by weight of silicone oil.
更に脂肪酸モノグリセライドを0.1〜5゜0重量%含
有させることが好ましい。Furthermore, it is preferable to contain 0.1 to 5.0% by weight of fatty acid monoglyceride.
抗菌剤としては、ヒノキチオール、感光素201号、ア
ビエチン酸、ロジン、およびレゾルシンからなる群から
選んだ少なくとも1種を使用することが好ましい。As the antibacterial agent, it is preferable to use at least one selected from the group consisting of hinokitiol, photosensor No. 201, abietic acid, rosin, and resorcinol.
本発明においては、界面活性剤を配合しないので、抗菌
剤の能力を最大限に発揮させ、抗菌剤量も減少させる、
従ってこの面においても安全性及び有効性を向上させる
ことができる。In the present invention, since no surfactant is blended, the ability of the antibacterial agent is maximized and the amount of antibacterial agent is reduced.
Therefore, safety and effectiveness can be improved in this aspect as well.
また、合成ベントナイト、シリコン抽は官能面てし本発
明の目的に合致している。In addition, synthetic bentonite and silicone extracts have a functional surface and meet the purpose of the present invention.
合成ベントナイトとしては、前記のケイ酸マグネシウム
、リチウムを使用することが好ましい。As the synthetic bentonite, it is preferable to use the above-mentioned magnesium silicate and lithium.
シリコン油とは、ジメチルポリシロキサン、メチルフェ
ニルポリシロキサン等一般にシリコン油と呼ばれる原料
であればよく、重合度すなわち、粘度は特に限定はなく
、他の原料との組み合わせ、出来上りの製品の目的によ
り選択すればよい。The silicone oil may be any raw material commonly called silicone oil such as dimethylpolysiloxane or methylphenylpolysiloxane, and the degree of polymerization, that is, the viscosity, is not particularly limited and can be selected depending on the combination with other raw materials and the purpose of the finished product. do it.
また、合成ベントナイトの分散はなかなか容易ではなく
、マイクロフルイダイザーを利用することによって容易
に均一にできる。Furthermore, it is not easy to disperse synthetic bentonite, but it can be easily uniformized by using a microfluidizer.
また乳化に際しては、皮膚外用剤全体をマイクロフルイ
ダイザーを通して乳化しても同一の効果が得られる。マ
イクロフルイダイザーを使用しての乳化によって、ゲル
強度が上昇し、合成ベントナイトの配合量が少なくてす
み、コスト而ばかりでなく、皮膚官能面からも優れた結
果が青られる。Furthermore, when emulsifying, the same effect can be obtained even if the entire skin external preparation is emulsified through a microfluidizer. Emulsification using a microfluidizer increases gel strength, requires less synthetic bentonite, and provides superior results not only from a cost perspective but also from a skin sensory perspective.
本発明の皮膚外用剤の乳化においては界面活性剤を用い
ていないので物理的に粒子を細かくすることも大きな要
因であるのでマイクロフルイダイザーの活用によって、
強い乳化力がある方がよりよいことは勿論である。Since no surfactant is used in the emulsification of the skin external preparation of the present invention, physically making the particles finer is also a major factor, so by using a microfluidizer,
Of course, it is better to have strong emulsifying power.
本発明の皮膚外用剤はシリコン浦を配合することによっ
て、粒子が細かくなり、増粘作用を生じ、合成ベントナ
イトの配合量も少なくてすむ。By incorporating silicone into the skin external preparation of the present invention, the particles become fine and a thickening effect is produced, and the amount of synthetic bentonite to be incorporated can be reduced.
この結果、シリコン浦が持つのびのよさに加え、合成ベ
ントナイトの配合量の減少による同物質がもつきしみ感
が減少し、粘度の機構がゲルによるもの以外の要素が入
るためと、粒子の細かさによって、安定性が改良され、
且つ物性も改良される。As a result, in addition to the spreadability that Siliconura has, the reduction in the amount of synthetic bentonite blended with the same substance reduces the sticky feeling, and the viscosity mechanism incorporates elements other than gel, and the fineness of the particles. The stability is improved by
Moreover, the physical properties are also improved.
また脂肪酸モノグリセライドを配合すると粘度か上昇し
、官能面でも浦感を与え、他の類似の原料では得られな
い安定性と官能が得られ、その有効性は高い。脂肪酸と
しては炭素数12から22の範囲であれば用いることが
できる。In addition, when fatty acid monoglyceride is added, the viscosity increases, and it also gives a feeling of freshness in terms of sensory aspects, providing stability and functionality that cannot be obtained with other similar raw materials, and its effectiveness is high. Any fatty acid having a carbon number of 12 to 22 can be used.
合成ベントナイトの配合量は他の原料、乳化法、分散法
によって影響されるが、外用剤全体に対して0.1〜5
.0重量%が好ましい。0.1重量06未満では乳化が
不十分となり、5.0重量%を超えると皮膚に使用した
時のきしみ感が強くなり好ましくない。The amount of synthetic bentonite blended is affected by other raw materials, emulsification method, and dispersion method, but it is 0.1 to 5% of the total external preparation.
.. 0% by weight is preferred. If it is less than 0.1% by weight, emulsification will be insufficient, and if it exceeds 5.0% by weight, it will give a strong squeaky feeling when used on the skin, which is not preferable.
シリコン油の配合量は、外用剤全体に対して2〜30重
量%が好ましい。2重量%未満では、官能的な改良が見
られず、乳化の向上もない。30重量%を超えると水相
との乳化が再び困難となると共に官能面で油感が強くな
って好ましくない。The amount of silicone oil blended is preferably 2 to 30% by weight based on the total external preparation. If it is less than 2% by weight, no sensory improvement is observed and no improvement in emulsification is observed. If it exceeds 30% by weight, emulsification with the aqueous phase becomes difficult again and the oily feeling becomes strong, which is not preferable.
本発明の皮膚外用剤に使用する抗菌剤としては、通常皮
膚外用剤に使用される抗菌剤であるヒノキチオール、感
光素201号、レゾルシン等が使用できる。皮膚疾患の
1つであるニキビの1つの原因は毛嚢内細菌が関係して
いるとされ、抗菌剤を配合したクリームや軟膏が利用さ
れている。本出願人はアビエチン酸やこれを含有するロ
ジンがニキビ治療用皮膚外用剤に配合する抗菌剤として
有効であり、副作用や感作性もなく安全性が高く、安定
であることを見い出し、別途出願している。As the antibacterial agent used in the external skin preparation of the present invention, hinokitiol, photosensor No. 201, resorcinol, etc., which are antibacterial agents usually used in external skin preparations, can be used. One cause of acne, a skin disease, is thought to be related to bacteria within hair follicles, and creams and ointments containing antibacterial agents are used. The applicant has discovered that abietic acid and rosin containing it are effective as antibacterial agents in external skin preparations for acne treatment, and are highly safe and stable without side effects or sensitization, and have filed a separate application. are doing.
本発明の皮膚外用剤に配合する抗菌剤としてもこのアビ
エチン酸やこれを含有するロジンを使用すると、抗菌力
を阻害することなく、安定な乳化物が得られ、Prop
ionibacterium acnes。When this abietic acid or a rosin containing it is used as an antibacterial agent in the skin external preparation of the present invention, a stable emulsion can be obtained without inhibiting antibacterial activity, and the propagation
ionibacterium acnes.
5taphylococcus aureus、 5t
aphylococcus eojdermi−dis
などの毛嚢内細菌に有効である。 抗菌剤の使用量
としては、抗菌剤の種類により大きく異なるが、外用剤
全体に対して0.005〜5重量%の範囲である。5taphylococcus aureus, 5t
aphylococcus eojdermi-dis
It is effective against bacteria in hair follicles such as. The amount of antibacterial agent used varies greatly depending on the type of antibacterial agent, but is in the range of 0.005 to 5% by weight based on the total external preparation.
合成ペン!・ナイト、シリコン抽以外の原料は面性原料
については特に制限はなく、液体油では流動パラフィン
、スクワラン、オリーブ浦、ホホバ油、サフラワー油、
ミンク油、ミリスチン酸ミリスチル、トリグリセライド
等があり、固体油としてはパラフィン、セレシン、みつ
ろう、ゲイロウ、脂肪酸、高級アルコール等があり、そ
の他添加薬剤、香料、防腐剤、酸化防止剤等を陀合し得
る。Synthetic pen!・There are no particular restrictions on raw materials other than night and silicon extraction, and liquid oils include liquid paraffin, squalane, olive ura, jojoba oil, safflower oil,
Mink oil, myristyl myristate, triglyceride, etc. are included, and solid oils include paraffin, ceresin, beeswax, gay wax, fatty acids, higher alcohols, etc. Other additives, fragrances, preservatives, antioxidants, etc. can be added. .
これらの原料を目的により選択するが、同胞の量比は、
製品の物性に影響するので、その配合量は目的に合わせ
て調整する。These raw materials are selected depending on the purpose, but the quantitative ratio of the compatriots is
Since it affects the physical properties of the product, its amount should be adjusted according to the purpose.
また、ニキビ治療用皮膚外用剤のような用い方をすると
きは、油剤は少ない方がよいのは勿論である。Furthermore, when used as an external skin preparation for treating acne, it is of course better to use less oil.
水性原料は合成ベントナイトのゲル強度が変化するので
、その配合は製品の物性に影響する。Since aqueous raw materials change the gel strength of synthetic bentonite, their formulation affects the physical properties of the product.
まず多価アルコールであるが、たとえばゲル強度の高い
順番に記述すると、グリセリン、1,3ブチレングリコ
ール、PEG100Oになる。First, polyhydric alcohols are listed in descending order of gel strength: glycerin, 1,3-butylene glycol, and PEG100O.
これらを量や製品使用用途により単独或いは2種以上併
用して最適な条件を選択する。Optimal conditions are selected by using these alone or in combination of two or more depending on the amount and purpose of use of the product.
またゲル形成には電解質の濃度が影響し、イオンの種類
によって最適条件が異なるので、イオンの種類と量を選
択すれば、合成ベントナイトの使用量が少なくてすむ。In addition, gel formation is affected by the concentration of the electrolyte, and the optimum conditions differ depending on the type of ion, so if the type and amount of ions are selected, the amount of synthetic bentonite used can be reduced.
電H質の添加は、上記のような効果を示すが、本発明の
効果に直接は影響しないので、必ずしも添加は必須では
ないが、添加した方が、合成ベントナイトの配合量が減
量できるので好ましい。Although the addition of an electrolyte exhibits the above-mentioned effects, it does not directly affect the effects of the present invention, so its addition is not essential, but it is preferable to add it because it allows the amount of synthetic bentonite to be reduced. .
実施例においては、防腐剤として、パラオキシ安息香酸
メチルを用いて、電解質としての役割を果させているが
、防腐剤は必ずしも必要としないので、他の電解質でも
同等問題はない。In the examples, methyl paraoxybenzoate is used as a preservative to play the role of an electrolyte, but since a preservative is not necessarily required, other electrolytes may be used without the same problem.
また、pHは5.5以下になると、凝集を起すので、こ
れ以下のpHでは安定な製品は得られない。Furthermore, if the pH is lower than 5.5, aggregation occurs, so a stable product cannot be obtained at a pH lower than this.
しかしながら、合成ベントナイトがpH緩衝作用があり
、またこれを水溶液にしたときはpHは8.5前後にな
るので、特にpHに影響を与える原料を配合しないとき
は、pHの調整は必要がない。However, synthetic bentonite has a pH buffering effect, and when it is made into an aqueous solution, the pH is around 8.5, so there is no need to adjust the pH, especially when no raw materials that affect the pH are mixed.
さらに、水溶性高分子も種類によっては、ゲルを破壊す
るものもあり、ここで有効な水溶性高分子は、例えばカ
ルボキシメチルセルロース、ポリビニルアルコール等が
挙げられる。Furthermore, some types of water-soluble polymers can destroy gels, and effective water-soluble polymers include, for example, carboxymethyl cellulose, polyvinyl alcohol, and the like.
水溶性添加薬剤も、前記のような注意をして配合する必
要がある。Water-soluble additives also need to be blended with the above-mentioned precautions.
以下に実施例によって、本発明を更に具体的に説明する
が、本発明は、この実施例によって同等限定されるもの
ではない。数値は、特に指示しない限り、重量基準(重
量部等)である。EXAMPLES The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited to the same extent by these Examples. Unless otherwise specified, numerical values are based on weight (parts by weight, etc.).
(実施例1) エモリエントクリームのIA スクワラ
ン 15.9グリセリン
モノステアレート 2.0ベヘニルア
ルコール 2.0ジメチルポリ
シロキサン(100cps) 10. 0ロジン
0.1B 合成
ベントナイト 1.0精製
水 48.813ブ
チレングリコール 20.O防腐剤(バ
ラオキシ安息香酸メチル)0.2合成ベントナイトを精
製水によく分散した後、AとBそれぞれを計量し、約7
0℃に加温し、Bを攪拌しつつ、Aを徐々に加えて乳化
し、室温まで冷却する。(Example 1) IA of emollient cream Squalane 15.9 Glycerin monostearate 2.0 Behenyl alcohol 2.0 Dimethyl polysiloxane (100 cps) 10. 0 Rosin 0.1B Synthetic bentonite 1.0 Purified water 48.813 Butylene glycol 20. O Preservative (Methyl Baroxybenzoate) 0.2 After well dispersing synthetic bentonite in purified water, weigh A and B each, and approximately 7
Heat to 0°C, and while stirring B, gradually add A to emulsify, and cool to room temperature.
(実施例2) エモリエントクリームの2A アビエチ
ン酸 0.1ジメチルポ
リシロキサン(100cps) 5. OB
合成ベントナイト 2.
0猜製氷 78.7
グリセリン 3・5プロ
ピレングリコール 7. 01
%ハイビスワコー105水溶液 1.0(N
aOH中和液)
C胎盤抽出液 2.O
D 香料 0.
5合成ベントナイトを精製水によく分散した後、AとB
それぞれを計量し、約70℃に加温し、Bを攪拌しつつ
、Aを徐々に加えて約60℃になったらCとDを加えて
室温まで冷却する。(Example 2) 2A of emollient cream Abietic acid 0.1 dimethyl polysiloxane (100 cps) 5. OB
Synthetic bentonite 2.
0 ice cubes 78.7
Glycerin 3.5 propylene glycol 7. 01
% Hibis Wako 105 aqueous solution 1.0 (N
aOH neutralized solution) C Placenta extract 2. O
D Fragrance 0.
5 After well dispersing the synthetic bentonite in purified water, A and B
Weigh each and heat to about 70°C. While stirring B, gradually add A. When the temperature reaches about 60°C, add C and D and cool to room temperature.
(実施例3) 乳 液
A スクワラン 1.
0オリーブ油 1
802−エチルヘキサン酸トリグリセライド 1.
0セタノール 1・
0ミツロウ 0.
5メチルフエニルポリシロキサン 2.0
ジメチルポリシロキサン(100cps) 3
. 0酸化防止剤 0
. 2感光素201号 0
.0ルゾルシン 0
.IB 合成ベントナイト
2. 0精製水 7
4.49グリセリン 8
,0ジプロピレングリコール 5
.0カルボキシメチルセルロース 0.
5(1,0%水溶液)
防腐剤(バラオキシ安息香酸メチル)0.2合成ベント
ナイトを精製水によく分散した後、AとBそれぞれを計
量し、約70℃に加温し、Aを攪拌しつつ、Bを徐々に
加えて室温まで冷却する。(Example 3) Emulsion A Squalane 1.
0 olive oil 1
802-Ethylhexanoic acid triglyceride 1.
0 cetanol 1.
0 beeswax 0.
5 methyl phenyl polysiloxane 2.0
Dimethylpolysiloxane (100cps) 3
.. 0 antioxidant 0
.. 2 Photosensitive element No. 201 0
.. 0 Lusorcin 0
.. IB synthetic bentonite
2. 0 purified water 7
4.49 Glycerin 8
,0 dipropylene glycol 5
.. 0 carboxymethylcellulose 0.
5 (1.0% aqueous solution) Preservative (methyl roseoxybenzoate) 0.2 After well dispersing the synthetic bentonite in purified water, weigh each of A and B, heat to about 70°C, and stir A. At the same time, gradually add B and cool to room temperature.
(比較例1)
実施例1のエモリエントクリーム1を以下のごとく、原
料を変更したクリーム。(Comparative Example 1) A cream in which the raw materials of Emollient Cream 1 of Example 1 were changed as follows.
A スクワラン 22
.9グリセリンモノステアレート
2.0ベヘニルアルコール
2.0ジメチルポリシロキサン(100cps)
2. 0ロジン
ソルビタンモノステアレート
B ポリオキシエチレンソルビタンモノステアレー(2
0E、O,)
精製水
1.3ブチレングリコール
防腐剤(バラオキシ安息香酸メチル)
(比較例2)
実施例2のエモリエントクリーム2を以下のごとく原料
を変更したクリーム。A Squalane 22
.. 9 Glycerin monostearate
2.0 behenyl alcohol
2.0 dimethylpolysiloxane (100cps)
2. 0 Rosin Sorbitan Monostearate B Polyoxyethylene Sorbitan Monostearate (2
0E, O,) Purified water 1.3 Butylene glycol preservative (methyl roseoxybenzoate) (Comparative example 2) A cream obtained by changing the raw materials of the emollient cream 2 of Example 2 as follows.
A アビエチン酸
ジメチルポリシロキサン(100cps)ソルビタンモ
ノステアレート
B ポリオキシエチレン硬化ヒマシ浦(60E、0.)
精製水
グリセリン
プロピレングリコール
1%ハイビスワコー105水溶液
(NaOH中和液)
防腐i’FJ (バラオキシ安息香酸メチル)ト
44゜
20゜
C胎盤抽出液
D 香料
(比較例3)
実施例3の乳液を以下のごと
乳液。A: Dimethyl abietate polysiloxane (100 cps) Sorbitan monostearate B: Polyoxyethylene hardened Castor (60E, 0.)
Purified water Glycerin Propylene glycol 1% Hibis Wako 105 aqueous solution (NaOH neutralized solution) Preservative i'FJ (Methyl roseoxybenzoate) Placenta extract D at 44°20°C Fragrance (Comparative example 3) The emulsion of Example 3 is as follows. Nogoto emulsion.
A スクワラン
オリーブ油
2−エチルヘキサン酸トリグリセライドセタノール
ミツロウ
メチルフェニルポリシロキサン
ジメチルポリシロキサン(100cps)ソルビタンモ
ノステアレート
酸化防止剤
感光素201号
レゾルシン
B ポリオキシエチレンソルビタンモノステアレー(2
0E、0.)
ポリオキシエチレン硬化ヒマシ油(60E、O,)精製
水
く原料を変更した
ト
ロ2゜
4つ
グリセリン 8.0
ジプロピレングリコール
5. 0カルボキシメチルセルロース(1,0%水溶液
)10.5防腐剤(バラオキシ安息香酸メチル)0.2
上記の製剤から防腐剤(バラオキシ安息香酸メチル)を
除いて、抗菌剤を以下の濃度にした製剤を作成した。A Squalane Olive oil 2-Ethylhexanoic acid triglyceride Setanol Beeswax Methyl phenyl polysiloxane Dimethyl polysiloxane (100 cps) Sorbitan monostearate Antioxidant Photosensitizer No. 201 Resorcin B Polyoxyethylene Sorbitan monostearate (2
0E, 0. ) Polyoxyethylene hydrogenated castor oil (60E, O,) Purified water Toro 2゜4 Glycerin 8.0
dipropylene glycol
5. 0 Carboxymethylcellulose (1.0% aqueous solution) 10.5 Preservative (methyl hydroxybenzoate) 0.2
A preservative (methyl roseoxybenzoate) was removed from the above formulation to create a formulation containing the antibacterial agent at the following concentration.
作成したエマルジョン20gにProplonibac
te−rium acnesを1.0〜1.5X107
個接種し、37℃に放置した。24時間後、1週間後、
2週間後、3週間後に一部を取り出し生菌数を・a定し
た。培地は変法CA M培地を用い、放置、各操作は嫌
気的に行った。Add Proplonibac to 20g of the emulsion you created.
terium acnes 1.0~1.5X107
The cells were inoculated individually and left at 37°C. 24 hours later, 1 week later,
After 2 and 3 weeks, a portion was taken out and the number of viable bacteria was determined. A modified CAM medium was used as the medium, and each operation was performed anaerobically.
N:菌を検出せず N:菌を検出せず N:菌を検出せず 使用テスト その方法は二重冒険法を用いて実験した。N: No bacteria detected N: No bacteria detected N: No bacteria detected Usage test The method was tested using the double adventure method.
披険者Na 1〜16は実施例−1、披険者No、17
〜32は比較例−1である。Presenter Na 1 to 16 are Example-1, Presenter No. 17
-32 is Comparative Example-1.
判定基準としては有効性については以下のような基準と
した。The criteria for effectiveness were as follows.
ニキビの状態 改 善 度 刺激の有無十
−重度 −−悪化 −−刺激はない+十
−軽度 士 −変化なし 十 −若干刺激がある
++十 −中度 十 −やや改善 十十 −刺
激がある++千十 −やや重度 千十 −かなり改善
++十−かなり刺激がある+++++−重度 十
+十囃顕著な改善〔安全性試験〕
(方 法)
(1)細胞毒性試験
1)カバーガラスの入った6 amのシャレーにlEa
glc M E M (牛胎児血清20%)培地を5
mlづつ分注する。Acne condition Improvement degree Irritation or not
−Severe −−Worse −−No irritation +10
- Mild - No change 10 - Slight irritation + + 10 - Moderate 10 - Slight improvement 10 - Irritation + + 10 - Slightly severe 10 - Significant improvement ++ 10 - Considerable irritation + + + + - Severe 10 + Significant improvement [Safety test] (Method) (1) Cytotoxicity test 1) Place lEa in a chalet at 6 am with a cover glass.
glcMEM (fetal bovine serum 20%) medium
Dispense in ml.
2)JTC−17細胞浮遊液(30万個)を添加し5%
C0,36°C148時間培養する。2) Add JTC-17 cell suspension (300,000 cells) to 5%
Culture at CO, 36°C for 148 hours.
3)緩衝液PBS (−)(NaCN 8g。3) Buffer PBS (-) (NaCN 8 g.
KCN O,2g、Na PO1,15g。KCN O, 2g, Na PO 1, 15g.
4
KHPOO,2gを含む緩衝液)で2度洗4
浄
4)緩衝液PBS(−)で希釈した試料3 mlを加え
、36℃、60分間培養する。4) Wash twice with buffer containing 2 g of KHPOO) 4) Add 3 ml of sample diluted with buffer PBS(-) and incubate at 36°C for 60 minutes.
5) Eagle MElvf (牛胎児血清20%)
培地を7 mlづつ分注し、5%Co、’36℃、48
時間培養する。5) Eagle MELvf (20% fetal bovine serum)
Dispense the medium into 7 ml portions and store in 5% Co, at 36°C, 48°C.
Incubate for hours.
6)固定、染色し判定する。6) Fix, stain and judge.
判定基準
〔1〕細胞数による判定
5core O: Control と同じ5core
1 : Control とほぼ同じ(僅に染色濃度
が劣る)
Score 2 : Controlの2/3位(肉眼
でも分かる程度に減少)
Score 3 : Controlとほぼ半分(大幅
に減少)
Score 4 : Controlの1/3位(細胞
数はごく僅か)
Score 5 :細胞を認めない
(全く、または殆ど認めない)
〔2〕細胞形態による判定
5core O:正常像
5core 1 :異常細胞が僅かに認められる(正常
細胞が80%以上)
Score 2 :異常細胞が認められる(正常細胞が
50%〜80%位)
Scorp 3 :異常細胞が多数認められる(正常細
胞が20%〜5096位)
殆ど異常細胞である。Judgment criteria [1] Judgment based on cell number 5 cores O: Same 5 cores as Control
1: Almost the same as Control (slightly inferior staining density) Score 2: 2/3 of Control (decreased enough to be visible to the naked eye) Score 3: Almost half of Control (significantly decreased) Score 4: 1/1 of Control 3rd place (very few cells) Score 5: No cells observed (no or almost no cells observed) [2] Judgment based on cell morphology 5core O: Normal image 5core 1: Slight abnormal cells observed (normal cells 80% or more) Score 2: Abnormal cells are observed (normal cells are around 50% to 80%) Scorp 3: Many abnormal cells are observed (normal cells are around 20% to 5096th) Most of the cells are abnormal.
(正常細胞が10%位)
Scorp 5 :正常細胞を認めない表示の仕方は最
初の数字は細胞数による判定結果を、括弧内の数字は細
胞形態による判定結果を示す。(Normal cells are approximately 10%) Scorp 5: Normal cells are not recognized The first number indicates the determination result based on the number of cells, and the number in parentheses indicates the determination result based on cell morphology.
(2)人クローズドパッチテスト
1)プラスター(フィンチャンバー)に検体を塗布し、
上腕内側部に貼布し24時間放置する。(2) Human closed patch test 1) Apply the sample to the plaster (fin chamber),
Apply it on the inside of your upper arm and leave it for 24 hours.
2)プラスターを剥離除去し1時間放置する。2) Peel off the plaster and leave it for 1 hour.
(iり定方性)
判定刺激点
0.00 反応なし
0.00 疑わしい紅斑、僅かな紅斑
0.50 軽い紅斑
紅斑
紅斑子W腫
紅斑+浮腫十丘疹、漿液性丘
疹、小水庖
0
0
2゜
上
+
0
3゜
+
corp
刺激率−刺激点の合計/総人数×100(3)ウサギク
ローズドバッチテスト
日本白色種ウサギ6羽を用いる。背部皮膚を電気バリカ
ンで刈上し、動物用パッチテスト 創膏に検体を0.2
m1滴下し皮膚に24時間貼布する。(Iritisotropy) Judgment irritation point 0.00 No reaction 0.00 Suspicious erythema, slight erythema 0.50 Mild erythema, erythema, erythema, W tumor, erythema + edema papules, serous papules, small varicella 0 0 2 ° above + 0 3 ° + corp Stimulation rate - total stimulation points / total number of people x 100 (3) Rabbit closed batch test Six Japanese white rabbits were used. Trim the back skin with electric clippers and apply 0.2 of the sample to the veterinary patch test wound.
Add 1ml drop and apply it to the skin for 24 hours.
判定は貼布除去後、1.24.48.72時間目に以下
の基準で行う。Judgment is made based on the following criteria at 1.24.48.72 hours after removal of the patch.
(判定基準)
紅 斑
5core O:紅斑なし
5core 1 :ごく軽度な紅斑(やっと認められる
程度)
Score 2 :明らかな紅斑
5core 3 :中程度から強い紅斑5core 4
:深紅色の強い紅斑に軽い面皮形成(障害は深部に)
Score
Score
0:浮腫なし
1:ごく軽度な浮腫
程度)
(やっと認められる
5core 2 :明らかな浮腫(周囲と明らかに区分
可能)
Score 3 :中程度の浮腫(1mm程盛り上がっ
ている)
Score 4 :強い浮腫(1mm以上盛り上がり、
周囲にも広がる)
(4)モルモット連続塗布試験
1)ハートレー系白色モルモット6匹を用い、背部およ
び側腹部皮膚を電気バリカンおよびシェーバ−で除毛し
、綿棒で直径2cmの面積内に塗布する。(Judgment criteria) Erythema 5core O: No erythema 5core 1: Very mild erythema (barely noticeable) Score 2: Obvious erythema 5core 3: Moderate to strong erythema 5core 4
: Strong crimson erythema with mild face skin formation (disorder is deep) Score Score 0: No edema 1: Very mild edema) (Finally recognized 5core 2: Obvious edema (clearly distinguishable from the surrounding area) Score 3 : Moderate edema (raised by about 1mm) Score 4 : Strong edema (raised by more than 1mm,
(4) Guinea pig continuous application test 1) Using 6 Hartley white guinea pigs, the skin on the back and flanks is removed with electric clippers and a shaver, and the skin is applied within a 2 cm diameter area with a cotton swab.
2)この塗布を1日1回3日間連続して実施する。2) Apply this application once a day for 3 consecutive days.
(ill 定)
(判定基準)
紅斑と浮腫を行うが、ウサギクローズドバッチテストと
同じ。(ill determined) (Judgment criteria) Erythema and edema are measured, but same as rabbit closed batch test.
累積刺激指数は72 It r後、9BHr後、16B
tlr後の5coreの平均値である。Cumulative stimulation index was 72 after Itr, after 9BHr, after 16B
This is the average value of 5 cores after tlr.
(結 果)
2)人クローズドバッチテスト
3)
ウサギクローズドパッチテスト
4)モルモット連続塗布試験
〔発明の効果〕
本発明の皮膚外用剤においては、抗菌剤の効果を減少さ
せることなく乳化させ得る、即ち少量の抗菌剤の配合で
抗菌力を保持しながら乳化した皮膚外用剤か得られる。(Results) 2) Human closed batch test 3) Rabbit closed patch test 4) Guinea pig continuous application test [Effects of the invention] In the skin external preparation of the present invention, it is possible to emulsify the antibacterial agent without reducing its effectiveness. By adding a small amount of antibacterial agent, it is possible to obtain an emulsified skin preparation that maintains antibacterial activity.
本発明の皮膚外用剤は、通常の界面活性剤を使用するこ
となく乳化物が安定であり、キメが細かく、きしみ感な
ど使用に当っての不快感がなく、クリーム、乳液等とし
ての物性において優れ、しかも、皮膚に対し安全性が保
証されている。The skin external preparation of the present invention has a stable emulsion without the use of ordinary surfactants, has a fine texture, does not cause discomfort when used such as a squeaky feeling, and has good physical properties as a cream, emulsion, etc. It is excellent and is guaranteed to be safe for the skin.
抗菌剤配合皮膚外用剤として、ニキビ治療用皮膚外用剤
があるが、本発明の皮膚外用剤は消削の配合を少くでき
、官能面でもさっばりした感触を与える、油感の少ない
抗菌剤配合皮膚外用剤である。As external skin preparations containing antibacterial agents, there are external skin preparations for acne treatment, but the skin external preparation of the present invention contains antibacterial agents with less oily feeling and can reduce the amount of shavings, giving a light feel on the sensory side. It is an external preparation for the skin.
Claims (1)
とを配合してなる皮膚外用剤。 2、合成ベントナイトを0.1〜5.0重量%含有して
なる請求項1記載の皮膚外用剤。 3、シリコン油を2〜30重量%含有してなる請求項1
または2記載の皮膚外用剤。 4、脂肪酸モノグリセラードを0.1〜 5.0重量%含有してなる請求項1、2、3の何れかに
記載の皮膚外用剤。 5、抗菌剤が、ヒノキチオール、感光素 201号、アビエチン酸、ロジン、およびレゾルシンか
らなる群から選んだ少なくとも1種である請求項1、2
、3、4の何れかに記載の皮膚外用剤。[Scope of Claims] 1. An external skin preparation comprising at least synthetic bentonite, silicone oil, and an antibacterial agent. 2. The external preparation for skin according to claim 1, which contains 0.1 to 5.0% by weight of synthetic bentonite. 3. Claim 1 containing 2 to 30% by weight of silicone oil
or the skin external preparation according to 2. 4. The skin external preparation according to any one of claims 1, 2 and 3, which contains 0.1 to 5.0% by weight of fatty acid monoglyceride. 5. Claims 1 and 2, wherein the antibacterial agent is at least one selected from the group consisting of hinokitiol, photosensor No. 201, abietic acid, rosin, and resorcinol.
The skin external preparation according to any one of , 3 and 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28480689A JPH03148208A (en) | 1989-11-02 | 1989-11-02 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28480689A JPH03148208A (en) | 1989-11-02 | 1989-11-02 | External preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH03148208A true JPH03148208A (en) | 1991-06-25 |
Family
ID=17683256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP28480689A Pending JPH03148208A (en) | 1989-11-02 | 1989-11-02 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH03148208A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0818987A4 (en) * | 1995-04-03 | 2000-05-03 | Ascent Pharma Inc | Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions |
JP2005187340A (en) * | 2003-12-24 | 2005-07-14 | Otoo Sakakibara | Hair cosmetic and method for producing the same |
WO2008023610A1 (en) * | 2006-08-24 | 2008-02-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | External reparation for skin |
US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
US9926538B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61225110A (en) * | 1985-03-29 | 1986-10-06 | Shiseido Co Ltd | Composition containing photo-sensitive element |
JPS61236710A (en) * | 1985-04-12 | 1986-10-22 | Shiseido Co Ltd | Stabilized resorcin compounding agent |
JPH01180237A (en) * | 1988-01-12 | 1989-07-18 | Shiseido Co Ltd | Water-in-oil type emulsion composition |
-
1989
- 1989-11-02 JP JP28480689A patent/JPH03148208A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61225110A (en) * | 1985-03-29 | 1986-10-06 | Shiseido Co Ltd | Composition containing photo-sensitive element |
JPS61236710A (en) * | 1985-04-12 | 1986-10-22 | Shiseido Co Ltd | Stabilized resorcin compounding agent |
JPH01180237A (en) * | 1988-01-12 | 1989-07-18 | Shiseido Co Ltd | Water-in-oil type emulsion composition |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0818987A4 (en) * | 1995-04-03 | 2000-05-03 | Ascent Pharma Inc | Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions |
US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
JP2005187340A (en) * | 2003-12-24 | 2005-07-14 | Otoo Sakakibara | Hair cosmetic and method for producing the same |
JP4628671B2 (en) * | 2003-12-24 | 2011-02-09 | 乙雄 榊原 | Hair cosmetics |
US9926538B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US9926537B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US10160958B2 (en) | 2005-04-11 | 2018-12-25 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
WO2008023610A1 (en) * | 2006-08-24 | 2008-02-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | External reparation for skin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3108632B2 (en) | Stable composition containing ascorbic acid | |
US5695771A (en) | Composition containing a non-photocatalytic metal oxide and tocopherol its use in treating light induced signs of aging | |
US5919487A (en) | Nanoparticles coated with a lamellar phase based on silicone surfactant and compositions containing them | |
US5925679A (en) | Topical vehicles containing solubilized and stabilized azelaic acid | |
JP3004206B2 (en) | Composition for treating skin spots and / or aging and uses thereof | |
US6582709B1 (en) | Cream composition comprising Dead Sea Mud | |
EP2213335A2 (en) | Personal care compositions having reduced eye irritation | |
JPS60202806A (en) | Whitening cosmetic | |
EP0215108B1 (en) | Compositions for treating acne vulgaris and methods of making same | |
JPH06502874A (en) | Compositions providing sustained cosmetic and/or pharmaceutical treatment of the upper epidermal layers by topical administration to the skin | |
JP3199705B2 (en) | Compositions in the form of water-in-oil emulsions having varying shear rates | |
JPH03148208A (en) | External preparation for skin | |
CA2365660A1 (en) | Treatment for skin | |
KR20200125628A (en) | Compositions and methods of use to provide skin care benefits | |
CA2268030A1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
JP2001139446A (en) | Skin cosmetic kit | |
JP2000159632A (en) | Skin antimicrobial composition | |
CA2371917C (en) | After shave composition containing aluminum chlorohydrate | |
JPH08183726A (en) | Skin preparation for external use | |
KR0125008B1 (en) | Dermatological liposome composition containing pregnenolone | |
JPH0840824A (en) | Cosmetic | |
JPH03275609A (en) | Skin cosmetic | |
JPH0383909A (en) | Cosmetic and its production | |
JP2004210730A (en) | Oily liquid cosmetic | |
JP2001059054A (en) | Composition in form of water-in-oil type emulsion having developmental shear rate |